Insider at

04

Insider transactions

05
0 buys (P) 4 sells (S) Net: $-3,337,929 + 43 non-open-market transactions below last 12 months, based on the transactions shown below

Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted

43 other filings hidden
DateTickerCodeSharesPriceValue Owned afterΔ ownA/Dvs now
Jan. 12, 2026 ZYME S 30,424 $22.67 $689,712 226,842 Direct -11.83% Disposed 10.9% (price as of 2026-10-02)
Jan. 5, 2026 ZYME S 31,686 $25.10 $795,319 193,266 Direct -14.09% Disposed 0.2% (price as of 2026-10-02)
Jan. 5, 2026 ZYME S 22,657 $25.10 $568,691 158,286 Direct -12.52% Disposed 0.2% (price as of 2026-10-02)
Dec. 22, 2025 ZYME S 47,528 $27.02 $1,284,207 133,275 Direct -26.29% Disposed -6.9% (price as of 2026-10-02)
Jan. 6, 2025 ZYME S 33,406 $14.92 $498,418 80,803 Direct -29.25% Disposed 68.6% (price as of 2026-10-02)
Jan. 6, 2025 ZYME S 23,885 $14.92 $356,364 47,543 Direct -33.44% Disposed 68.6% (price as of 2026-10-02)
Jan. 8, 2024 ZYME S 5,706 $11.22 $64,021 23,762 Direct -19.36% Disposed 124.2% (price as of 2026-10-02)
Jan. 5, 2024 ZYME S 18,198 $10.65 $193,809 29,468 Direct -38.18% Disposed 136.2% (price as of 2026-10-02)
Sept. 9, 2020 MGNX S 13,849 $27.11 $375,446 0 Direct -100.00% Disposed -86.8% (price as of 2026-10-02)
Sept. 9, 2020 MGNX S 6,924 $27.11 $187,710 0 Direct -100.00% Disposed -86.8% (price as of 2026-10-02)
Oct. 16, 2013 MGNX P 46,875 $16.00 $750,000 46,875 Indirect · Acquired -77.6% (price as of 2026-10-02)

P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding

Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.

Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.

06
DateTickerSecurityUnderlying Exercise priceExpirationSharesA/D
Jan. 12, 2026 ZYME Restricted Stock Unit Common Stock (144,000) · · 144,000 Acquired
Jan. 12, 2026 ZYME Performance Stock Unit Common Stock (222,000) · · 222,000 Acquired
Jan. 12, 2026 ZYME Stock Option (Right to Buy) Common Stock (216,000) $23.16 Jan. 11, 2036 216,000 Acquired
Jan. 12, 2026 ZYME Restricted Stock Unit Common Stock (64,000) · · 64,000 Disposed
Jan. 5, 2026 ZYME Restricted Stock Unit Common Stock (66,666) · · 66,666 Disposed
Jan. 5, 2026 ZYME Restricted Stock Unit Common Stock (47,668) · · 47,668 Disposed
Dec. 22, 2025 ZYME Restricted Stock Unit Common Stock (100,000) · Dec. 22, 2025 100,000 Disposed
Jan. 10, 2025 ZYME Restricted Stock Unit Common Stock (192,000) · · 192,000 Acquired
Jan. 10, 2025 ZYME Stock Option (Right to Buy) Common Stock (288,000) $13.22 Jan. 9, 2035 288,000 Acquired
Jan. 6, 2025 ZYME Restricted Stock Unit Common Stock (66,666) · · 66,666 Disposed
Jan. 6, 2025 ZYME Restricted Stock Unit Common Stock (47,666) · · 47,666 Disposed
Jan. 5, 2024 ZYME Restricted Stock Unit Common Stock (200,000) · · 200,000 Acquired
Jan. 5, 2024 ZYME Stock Option (Right to Buy) Common Stock (300,000) $10.56 Jan. 4, 2034 300,000 Acquired
Jan. 5, 2024 ZYME Restricted Stock Unit Common Stock (47,666) · · 47,666 Disposed
Jan. 5, 2023 ZYME Restricted Stock Unit Common Stock (143,000) · · 143,000 Acquired
Jan. 5, 2023 ZYME Stock Option (Right to Buy) Common Stock (215,000) $8.00 Jan. 4, 2033 215,000 Acquired
Dec. 22, 2022 ZYME Restricted Stock Unit Common Stock (100,000) · Dec. 22, 2025 100,000 Acquired
May 13, 2021 MGNX Stock Option (right to buy) Common Stock (15,000) $28.88 May 13, 2031 15,000 Acquired
Sept. 9, 2020 MGNX Stock Option (right to buy) Common Stock (13,849) $16.00 Oct. 9, 2023 13,849 Disposed
Sept. 9, 2020 MGNX Stock Option (right to buy) Common Stock (6,924) $20.15 June 5, 2024 6,924 Disposed
May 14, 2020 MGNX Stock Option (right to buy) Common Stock (15,000) $24.97 May 14, 2030 15,000 Acquired
May 16, 2019 MGNX Stock Option (right to buy) Common Stock (10,000) $18.00 May 16, 2029 10,000 Acquired
May 17, 2018 MGNX Stock Option (right to buy) Common Stock (10,000) $21.34 May 17, 2028 10,000 Acquired
May 18, 2017 MGNX Stock Option (right to buy) Common Stock (10,000) $19.57 May 18, 2027 10,000 Acquired
May 18, 2016 MGNX Stock Option (right to buy) Common Stock (8,500) $21.06 May 18, 2026 8,500 Acquired
May 20, 2015 MGNX Stock Option (right to buy) Common Stock (8,500) $32.34 May 20, 2015 8,500 Acquired
June 5, 2014 MGNX Stock Option (right to buy) Common Stock (6,924) $20.15 June 5, 2024 6,924 Acquired
Oct. 16, 2013 MGNX Series D-2 Convertible Preferred Warrants Common Stock (15,315) · Oct. 16, 2013 287,533 Disposed
Oct. 16, 2013 MGNX Series D-2 Convertible Preferred Stock Common Stock (204,207) · · 3,833,767 Disposed
Oct. 16, 2013 MGNX Series C Convertible Preferred Stock Common Stock (1,050,652) · · 19,724,839 Disposed
Oct. 9, 2013 MGNX Stock Option (right to buy) Common Stock (13,849) $16.00 Oct. 9, 2023 13,849 Acquired

Exercise/conversion price is blank when not applicable (e.g. RSUs).

Initial ownership (Form 3) 3 holdings

07

Securities held when first becoming an insider, per SEC Form 3.

DateTickerSecuritySharesOwnership
Oct. 9, 2013 MGNX Series C Convertible Preferred Stock→ Common Stock (19,724,839) 19,724,839 Indirect
Oct. 9, 2013 MGNX Series D-2 Convertible Preferred Stock→ Common Stock (3,833,767) 3,833,767 Indirect
Oct. 9, 2013 MGNX Series D-2 Convertible Preferred Warrants→ Common Stock · Indirect

Compensation (DEF 14A)

08

Matched by name from proxy statements (DEF 14A) — verify against the filing.

ZYME

CEO, President & Chair(4)
Fiscal yearSalaryBonusStock awards Option awardsNon-equity incentivePension changeOtherTotal
2024 $654,833 · · · $361,652 · $139,459 $5,253,616
2023 $625,452 · · · $321,651 · $89,146 $3,374,876
2022 $582,481 · · · $537,728 · $81,249 $7,125,457

Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.